Life and death by P53

BioEssays

Volumn 17, Issue 11, 1995, Pages 923-930

  Elledge, Richard M ^a   Lee, Wen‐Hwa ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; GENE THERAPY; GENETICS; HUMAN; MUTATION; NEOPLASM; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMAL; GENE THERAPY; GENES, P53; HUMAN; MUTATION; NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029395054     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.950171105     Document Type: Review

References (95)

1. Characterization of the human p53 gene
2. Structural aspects of the p53 protein in relation to gene evolution
3. p53 domains: Identification and characterization of two autonomous DNA‐binding regions
4. A proteolytic fragment from the central region of p53 has marked sequence‐specific DNA‐binding activity when generated from wild‐type but not from oncogenic mutant p53 protein
5. Crystal structure of a p53 tumor suppressor‐DNA complex: Understanding tumorigenic mutations
6. Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen
7. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain
8. A C‐terminal α‐helix plus basic region motif is the major structural determinant of p53 tetramerization
9. High‐resolution structure of the oligomerization domain of p53 by multidimensional NMR
10. p53 domains: Structure, oligomerization, and transformation
11. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis
12. Presence of a potent transcription activating sequence in the p53 protein
13. Functional domains of wild‐type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression
14. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
15. Adenovirus E1b‐58 kD antigen binds to p53 during infection of rodent cells: Evidence for an N‐terminal binding site on p53
16. Identification of p53 as a sequence‐specific DNA‐binding protein
17. Wild‐type p53 mediates positive regulation of gene expression through a specific DNA sequence element
18. WAF1, a potential mediator of p53 tumor suppression
19. Cyclin G is a transcriptional target of the p53 tumor suppressor protein
20. The p53‐mdm‐2 autoregulatory feedback loop
21. Sequence‐specific transcriptional activation is essential for growth suppression by p53
22. Wild‐type p53 binds to the TATA‐binding protein and represses transcription
23. Specific repression of TATA‐mediated but not initiator‐mediated transcription by wild‐type p53
24. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild‐type p53
25. p53 functions as a cell cycle control protein in osteosarcomas
26. 1 cyclin‐dependent kinases
27. p53 and DNA polymerase α compete for binding to SV40 T antigen
28. Mouse p53 inhibits SV40 origin‐dependent DNA replication
29. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen
30. Inhibition of DNA replication factor RPA by p53
31. A direct effect of activated human p53 on nuclear DNA replication
32. A p53‐dependent mouse spindle checkpoint
33. Induction of apoptosis by wild‐type p53 in a human colon tumor‐derived cell line
34. Wild‐type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53
35. p53‐Dependent apoptosis in the absence of transcriptional activation of p53‐target genes
36. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias
37. p53 status and the efficacy of cancer therapy in vivo
38. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild‐type p53 for radiosensitivity
39. Thymocyte apoptosis induced by p53‐dependent and independent pathways
40. Participation of p53 protein in the cellular response to DNA damage
41. Wild‐type p53 is a cell cycle checkpoint determinant following irradiation
42. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia‐telangiectasia
43. Wild‐type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
44. Mutant p53 proteins bind DNA abnormally in vitro
45. Oncogenic forms of p53 inhibit p53‐regulated gene expression
46. Analysis of p53 mutants for transcriptional activity
47. Wild‐type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions
48. Suppression of human colorectal carcinoma cell growth by wild‐type p53
49. p53‐dependent apoptosis suppresses tumor growth and progression in vivo
50. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines
51. Altered cell cycle arrest and gene amplification potential accompany loss of wild‐type p53
52. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
53. Functional inactivation of genes by dominant negative mutations
54. Meth A fibrosarcoma cells express two transforming mutant p53 species
55. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation
56. Cotranslation of activated mutant p53 with wild type drives the wild‐type p53 protein into the mutant conformation
57. Wild‐type p53 activates transcription in vitro
58. Use of the two‐hybrid system to identify the domain of p53 involved in oligomerization
59. Oligomerization of oncoprotein p53
60. p53 function and dysfunction
61. Structural and kinetic analysis of p53‐DNA complexes and comparison of human and murine p53
62. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53‐deficient mice
63. Equal transcription of wild‐type and mutant p53 using bicistronic vectors results in the wild‐type phenotype
64. Genetic mechanisms of tumor suppression by the human p53 gene
65. Wild‐type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles
66. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells
67. Detection of both mutant and wild‐type p53 protein in normal skin fibroblasts and demonstration of a shared ‘second hit’ on p53 in diverse tumors from a cancer‐prone family with Li‐Fraumeni syndrome
68. A dual role for p53 in the progression of human cells toward cancer
69. Alteration in a new gene encoding a putative membrane‐organizing protein causes neuro‐fibromatosis type 2
70. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors
71. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
72. Reconstitution of p53 expression in a nonproducer Ab‐MuLV‐transformed cell line by transfection of a functional p53 gene
73. Modulation of activity of the promoter of the human MDR1 gene by ras and p53
74. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
75. Inactive p53 mutants enhance the transcriptional activity of wild‐type p53
76. Hot‐spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle
77. Tumor cells transfected with a bacterial heat‐shock gene lose tumorigenicity and induce protection against tumors
78. The gene for the rat heat‐shock cognate, hsc70, can suppress oncogene‐mediated transformation
79. Different tumor‐derived p53 mutants exhibit distinct biological activities
80. Expression of wild‐type p53 in human A673 cells suppresses tumorigenicity but not growth rate
81. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild‐type p53
82. Wild‐type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin‐6
83. Induction of apoptosis by wild‐type p53 in a human colon tumor‐derived cell line
84. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus‐mediated transfer of the wild‐type p53 gene
85. Growth suppression of human breast cancer cells by the introduction of a wild‐type p53 gene
86. Expression of wild‐type p53 is not compatible with continued growth of p53‐negative tumor cells
87. The p53 proto‐oncogene can act as a suppressor of transformation
88. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild‐type p53 protein
89. Effects of exogenous wild‐type p53 on a human lung carcinoma cell line with endogenous wild‐type p53
90. Overexpression of wild‐type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus‐expressing cell lines
91. A retroviral wild‐type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
92. Therapeutic effect of a retroviral wild‐type p53 expression vector in an orthotopic lung cancer model
93. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
94. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
95. + cytotoxic T‐cells